Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
With their enhanced drug absorption and drug stability, Nemaura's easy-to-use transdermal technologies are expected to improve patient compliance and outcomes
LONDON, Dec. 7, 2016 /PRNewswire/ -- Based on its recent analysis of the transdermal drug delivery industry, Frost & Sullivan recognizes Nemaura Pharma Limited with the 2016 Europe Frost & Sullivan Award for Enabling Technology Leadership. Nemaura Pharma's transdermal drug delivery technologies plug the loopholes in traditional drug delivery technologies, especially in delivering biologics. Its solid and liquid microneedle-based drug delivery technologies, Memspatch and Micropatch respectively, facilitate minimally painful and minimally-invasive drug delivery with controlled drug dosage delivery.
Photo - http://photos.prnewswire.com/prnh/20161206/446144
Liquid biologic drug formulations are conventionally delivered through either syringes or pen injections, but they have proven to have many limitations and can result in treatment non-compliance and dosage variations. Nemaura Pharma addressed this gap in technology by rolling out the Memspatch transdermal drug delivery technology, which is enabled with multiple hollow microneedles in a compact, flat, box-like device.
"The Memspatch's needles have lower penetration depth than syringes and pen injectors, causing less pain. It reaches the microvessel network, which absorbs the drug faster than when delivered through normal syringes or injectors," said Frost & Sullivan Senior Research Analyst Debarati Sengupta. "Additionally, the hollow needles allow it to disperse the drug over a larger area, leading to rapid and almost instantaneous absorption into the blood stream. This is particularly helpful for diabetic patients."
Furthermore, the Memspatch comes with a disposable drug cartridge and non-disposable applicator. The applicator can be rolled over the skin, ensuring 100% needle penetration. It can aid the rapid or controlled slow delivery of liquid drug formulations from microlitres to tens of millilitres. Memspatch's drug dose accuracy and easy-to-use features make it more patient-friendly than competing solutions which increases patient compliance.
For solid drug formulations, Nemaura has developed the Micropatch. The company formulates liquid biologic drugs as well as small molecules into micro-solid dosage units that are hundreds of microns to millimetres in size, enhancing drug stability and requiring no refrigeration. The Micropatch solid drug delivery device has a sharp needle, and the solid drug is pelletized at its tip. The needle has to be inserted just under the skin, is minimally invasive, and ensures immediate delivery of a potent drug dose. The Micropatch offers 100% controlled dosing.
"Unlike biologics or peptide therapeutics, which are degraded by stomach acids if taken orally, transdermally-delivered drugs reduce the side effects by avoiding the first-pass effect of liver metabolism," noted Debarati. "The Micropatch does away with the need to maintain a cold chain, since the solid drug or vaccine is highly stable. With this easy-to-use device, the patients can administer the drugs themselves and do not require a specialist, eliminating costs incurred on the nursing and care staff."
Nemaura Pharma also has transdermal skin patches, delivering solid or liquid drugs. They are indicated for central nervous system conditions such as Alzheimer's and Parkinson's disease, as well as other chronic conditions such as hypertension. These transdermal patches are particularly useful for elderly patients who often forget to take medications on time. Instead of multiple dosages that need to be taken either daily or weekly, a single patch once a week or month can ensure high patient compliance.
Nemaura Pharma is currently working on developing a solid vaccine formulation and a peptide drug using its Micropatch drug delivery device as well as a skin cancer product delivered via its innovative microneedle technology. It has already received the CE certification for a microneedle-based skin prep/dermatology medical device and is developing a non-steroidal anti-inflammatory drug-based microneedle systems for joint inflammation.
Frost & Sullivan is pleased to recognise Nemaura Pharma for its continuous focus on leveraging technology to drive customer value and business impact.
Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend towards innovation, its relevance to the industry, and the positive impact on brand perception.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Nemaura Pharma Limited
A private specialist biotech company, Nemaura Pharma is strategically positioned to work with global pharmaceutical companies, as well as new biotechnology companies, to successfully bring both new and old drugs to patients in superior delivery formulations and systems. Ultimately, we aim to improve patient lifestyle and quality of life. Our advanced drug delivery systems are designed to increase the effectiveness and safety of therapeutic drugs, while also reducing complications due to patient non-compliance, and mitigating the side effects of less efficient delivery systems.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
Contact:
Chiara Carella
P: +44 (0) 207.343.8314
F: 210.348.1003
E: chiara.carella@frost.com
Share this article